CI
TEVA icon

Capital International’s Teva Pharmaceuticals TEVA Stock Holding History

Capital International’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-63,416
Closed -$561K – 166
2023
Q1 		$561K Hold
63,416
– – 0.03% 155
2022
Q4 		$578K Buy
63,416
+16,587
+35% +$145K 0.04% 151
2022
Q3 		$378K Buy
+46,829
New +$414K 0.03% 155
2021
Q3 		– Sell
-38,769
Closed -$384K – 161
2021
Q2 		$384K Sell
38,769
-19,444
-33% -$206K 0.02% 156
2021
Q1 		$672K Sell
58,213
-62,641
-52% -$718K 0.04% 147
2020
Q4 		$1.17M Buy
120,854
+8,409
+7% +$80.6K 0.07% 142
2020
Q3 		$1.01M Buy
112,445
+19,213
+21% +$203K 0.07% 145
2020
Q2 		$1.15M Buy
93,232
+33,832
+57% +$383K 0.11% 128
2020
Q1 		$533K Buy
+59,400
New +$609K 0.06% 155

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital International's TEVA Position: Q2 2023 in Review

Capital International sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 63,416 shares — an estimated $561K sold.

Capital International first reported a position in TEVA in Q1 2020 and held it in 9 quarters. The position peaked at $1.17M in Q4 2020. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Capital International reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Capital International sold 63,416 Teva Pharmaceuticals shares in Q2 2023, an estimated $561K.
  • Capital International first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Capital International's Teva Pharmaceuticals position peaked at $1.17M in Q4 2020.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Capital International's 13F filing for Q2 2023, filed 11 Aug 2023.